NexPoint Real Estate Finance (NREF) Q3 2024 earnings summary

Executive summary

• Net income attributable to common stockholders was $16.1 million ($0.74–$0.75 per diluted share) in Q3 2024, reversing a prior-year loss, driven by higher interest income and unrealized gains on investments.

• Earnings Available for Distribution (EAD) per diluted share rose to $0.75, and Cash Available for Distribution (CAD) per diluted share was $0.67, both up significantly year-over-year.

• Book value per share increased to $16.95 as of September 30, 2024.

• Declared a $0.50 per share dividend for Q3 and Q4 2024, with coverage ratios of 1.34x (CAD) and 1.50x–1.70x (EAD) for Q4 guidance.

• Portfolio totaled $1.1 billion across 83 investments, focused on multifamily, SFR, self-storage, and life sciences.

Financial highlights

• Net interest income for Q3 2024 was $12.5 million, up from $4.8 million in Q3 2023.

• Portfolio sector allocation: 52.3% multifamily, 26.7% life sciences, 17% SFR, with strong Sunbelt and top 50 MSA exposure.

• Sold a CMBS B-Piece with $82 million principal and 9.20% yield; funded $28.8 million on a life sciences property.

• Raised $42 million via Series B Preferred Shares; total Series B Preferred issued reached $121.5 million as of September 30, 2024.

• Debt outstanding was $815.5–$816 million, with a weighted average interest rate of 6.07% and average maturity of 1.4–1.6 years.

Outlook and guidance

• Q4 2024 guidance: EAD per diluted share at $0.79–$0.795 midpoint, CAD per share at $0.50–$0.505 midpoint.

• Estimated Q4 2024 net income attributable to common stockholders is $16.1 million–$18.4 million.

• Management expects sufficient liquidity for operations, debt service, and dividends over the next twelve months.

• Focus remains on originating and investing in target assets, with flexibility to re-allocate capital as market conditions evolve.

• Life sciences expected to remain 25–33% of portfolio on a fully levered basis.